Yescarta — Total revenues
Gilead Sciences Yescarta — Total revenues decreased by 9.5% to $332.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 14.0%, from $386.00M to $332.00M. Over 3 years (FY 2022 to FY 2025), Yescarta — Total revenues shows an upward trend with a 8.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market penetration and successful clinical adoption of the therapy, while a decrease may signal increased competition, pricing pressure, or shifts in treatment guidelines.
Detailed definition
This metric represents the total gross sales generated from the specific cell therapy product line within the company's...
Peer comparison
Comparable to revenue metrics for specialized oncology or cell therapy product lines at other major biopharmaceutical companies, often benchmarked against market share in specific cancer indications.
gild_segment_yescarta_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $290.00M | $290.00M | $290.00M | $290.00M | $374.50M | $374.50M | $374.50M | $374.50M | $380.00M | $414.00M | $387.00M | $389.00M | $386.00M | $393.00M | $349.00M | $367.00M | $332.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +29.1% | +0.0% | +0.0% | +0.0% | +1.5% | +8.9% | -6.5% | +0.5% | -0.8% | +1.8% | -11.2% | +5.2% | -9.5% |
| YoY Change | — | — | — | — | +29.1% | +29.1% | +29.1% | +29.1% | +1.5% | +10.5% | +3.3% | +3.9% | +1.6% | -5.1% | -9.8% | -5.7% | -14.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's yescarta — total revenues?
- Gilead Sciences (GILD) reported yescarta — total revenues of $332.00M in Q1 2026.
- How has Gilead Sciences's yescarta — total revenues changed year-over-year?
- Gilead Sciences's yescarta — total revenues decreased by 14.0% year-over-year, from $386.00M to $332.00M.
- What is the long-term trend for Gilead Sciences's yescarta — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's yescarta — total revenues has grown at a 8.8% compound annual growth rate (CAGR), from $1.16B to $1.50B.
- What does yescarta — total revenues mean?
- The total revenue generated from the sale of the company's specific CAR-T cell therapy product.